Meeting
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Combinatorial IL13Rα2 chimeric antigen receptor-T cells plus checkpoint blockade to treat solid tumors in murine and canine models.
Authors
Yibo Yin
University of Pennsylvania, Philadelphia, PA
Yibo Yin, Alina Boesteanu, Chong Xu, Avery Posey, Danielle Cook, Kristin Blouch, Bevin McGettigan-Croce, Nicola Mason, Carl H. June, Zhiguo Lin, Laura A. Johnson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells
Sub Track
Adoptive T-cell therapy: Modified and Unmodified Cells
Citation
J Clin Oncol 35, 2017 (suppl 7S; abstract 152)
DOI
10.1200/JCO.2017.35.7_suppl.152
Abstract #
152
Poster Bd #
H1
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
High-fidelity genome editing using NextGEN CRISPR (Clo51-dCas9) system for the production of allogeneic CAR-T cells.
First Author: Xinxin Wang
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Sustained, cell-intrinsic versus intermittent, cell-extrinsic checkpoint blockade in solid tumor CAR T-cell therapy.
First Author: Camille Linot
Poster
2017 ASCO Annual Meeting
Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).
First Author: Jerome Galon
Poster
2023 ASCO Annual Meeting
Presence of CD8+ cytotoxic T-cells in proximity to tumor cells, TIM3, CTLA-4 and prognostic implications for muscle-invasive urothelial cancer.
First Author: Nicolaus F. Debatin